Erectile Dysfunction: Serious Research for a Serious Problem

You have probably heard more than your share of Viagra jokes; a whole Web site is devoted to them. But impotence, or erectile dysfunction (ED), is no joke. According to a survey (H.A. Feldman et al., Journal of Urology, 151:54-61, 1994), more than 50 percent of men between 40 and 70 suffer from some degree of ED. The figure climbs to 67 percent at age 70. That's 20 to 30 million men, according to the National Institutes of Health. FIRST IN LINE: Viagra is actually the second drug approved t

Written byBarry Palevitz and Ricki Lewis
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

You have probably heard more than your share of Viagra jokes; a whole Web site is devoted to them. But impotence, or erectile dysfunction (ED), is no joke. According to a survey (H.A. Feldman et al., Journal of Urology, 151:54-61, 1994), more than 50 percent of men between 40 and 70 suffer from some degree of ED. The figure climbs to 67 percent at age 70. That's 20 to 30 million men, according to the National Institutes of Health.

By the end of the second quarter of 1998, Viagra sales accounted for more than $400 million of the company's $1 billion increase in total revenues compared to 1997. And by mid-August, 30 million pills had been dispensed. These figures reflect mainly domestic sales--38 other countries have now approved Viagra, including the 15 nations of the European Union, with 41 more expected by year's end. Financial analysts project a worldwide market ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies